The added value of <sup>18</sup>F-FDG PET/CT compared to <sup>68</sup>Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
نویسندگان
چکیده
Purpose: The 68Ga-PSMA PET/CT is a commonly used imaging modality in prostate cancers. However, few studies have compared the diagnostic efficiency between and 18F-FDG evaluated whether heterogeneous metabolic phenotype (especially PSMA-FDG+ lesions) exists patients with castration-resistant cancer (CRPC). We determined added value of to CRPC identified who may benefit from additional PET/CT. Methods: Data 56 underwent both May 2018 February 2021 were retrospectively analysed. Patients classified into two groups or without lesions. differences patient characteristics predictors having at least one lesion Results: Although detection rate (75.0% vs. 51.8%, P = 0.004) positive number (135 95) higher than PET/CT, there still 13/56 (23.2%) lesion. prostate-specific antigen (PSA) Gleason score lesions those (P 0.04 P<0.001, respectively). Multivariate regression analysis showed that (?8) PSA (?7.9 ng/mL) associated had 0.01 0.04, incidences low-probability (Gleason score<8 PSA<7.9 ng/mL), medium-probability score?8 ng/mL PSA?7.9 high-probability 0%, 21.7%, 61.5%, respectively (P<0.001). Conclusion: are significant for lesions, high
منابع مشابه
FDG PETCT in colorectal cancer
Colorectal cancer represents the second most common malignancy worldwide, with approximately one million newly diagnosed cases each year, and is the fourth leading cause of cancer mortality. This article provides an overview of the role of FDG (fluorodeoxyglucose) PET (positron emission tomography) CT (computed tomography) for assessment in patients with colorectal cancer. A summary of key lear...
متن کاملThe Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA
Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Nuclear Medicine
سال: 2021
ISSN: ['1535-5667', '0161-5505']
DOI: https://doi.org/10.2967/jnumed.121.262250